Achyrocline satureioides as an adjuvant therapy for the management of mild viral respiratory infections in the context of COVID‐19: Preliminary results of a randomized, placebo‐controlled, and open‐label clinical trial

Abstract

We evaluated the impact of an Achyrocline satureioides inflorescence infusion on the clinical outcomes of viral respiratory infections, including those caused by SARS‐CoV‐2, in a monocentric, randomized, open‐label, placebo‐controlled clinical trial. Patients with symptoms of viral respiratory infection, including suspected cases of COVID‐19, were included and assigned to receive either A. satureioides (n = 57) or Malus domestica (n = 67) infusions twice a day for 14 days. All participants were included before the RT‐PCR results, performed using a nasopharyngeal swab. The patients were further divided into subgroups according to real‐time polymerase chain reaction results: SARS‐CoV‐2‐positive and SARS‐CoV‐2‐negative subgroups for statistical analyses. We assessed clinical outcomes, such as the latency to resolution of cough, dyspnea, fever, sore throat, chest pain, smell and taste dysfunctions, diarrhea, nausea, abdominal pain, and loss of appetite; hospitalization; and mortality with questionnaires and medical records. The subjects that received early A. satureioides infusion showed a significant reduction in the average number of days with respiratory and neurological symptoms compared with the control group (M. domestica infusion). We conclude that A. satureioides is a safe agent and, in combination with standard care, improves viral respiratory infection symptoms, especially those related to COVID‐19.